公开(公告)号：EP2026842B1

公开(公告)日：2016-10-12

申请号：EP07746877.5

申请日：2007-06-12

申请人： Theraly Pharmaceuticals Inc.

发明人： LEE, Kang Choon ,  CHAE, Su Young ,  YOUN, Yu Seok ,  KIM, Won Bae ,  LEE, Sung Kwon

IPC分类号： A61K47/48 ,  A61P35/00 ,  A61P37/00 ,  A61P3/10 ,  A61P19/02 ,  C07K14/525

CPC分类号： A61K47/48215 ,  A61K38/19 ,  A61K38/191 ,  A61K47/60 ,  B01D15/361 ,  C07K14/52 ,  C07K14/525 ,  C07K14/70575 ,  C07K2319/73 ,  G01N30/96

摘要： Disclosed herein are an N-terminal modified PEG-TRAIL conjugate and a preparation method and use thereof. The PEG-TAIL conjugate has pharmaceutical activity identical or similar to that of native TRAIL (TNF-related apoptosis-inducing ligand) with extended in vivo half-life and enhanced stability. Compared to native TRAIL, the PEG-TAIL conjugate exhibits high solubility and solution stability, with highly improved pharmacokinetic profiles. Thus, the PEG-TAIL conjugate may be very useful for preventing and treating proliferative diseases and autoimmune diseases.